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The present case is of a 14-year-old female with trichotillomania (TTM) that was treated with a low dose of aripiprazole
(ARP) 1.5 mg/day. To our knowledge, this is the first published report to show an improvement of pubertal TTM using
an ultra-low dose of ARP. In this case, a 50-mg fluvoxamine monotherapy for 2 years and a subsequent 4-month
comprehensive cognitive behavioral therapy (CBT) monotherapy did not improve her hair-pulling symptoms. However,
the treatment with a low-dose ARP of 1.5 mg/day dramatically improved her TTM symptoms without extrapyramidal
symptoms. In this regard, low-dose ARP treatment for TTM might be a safe alternative to antidepressants, which carry
the risk of agitation with suicidal ideation in adolescents.
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Trichotillomania (TTM) is a poorly understood disorder
that is characterized using DSM-5 criteria as the recurrent
pulling out of one’s own hair [1]. The onset of hair pulling
in TTM usually coincides with or follows the onset of
puberty. TTM is associated with distress as well as with
social and occupational impairment [1]. Accumulating
evidence suggests that pharmacotherapy with selective
serotonin reuptake inhibitors (SSRIs), tricyclic antidepres-
sants (TCAs), antipsychotics, opioid-antagonists, or
glutamate modulators has the potential to improve TTM
in adults [2]. Recent empirical studies have also pointed to
the potential of cognitive behavioral therapy (CBT) for the
treatment of childhood TTM [3]. However, there is little
information available on the treatment of TTM in
puberty. In addition, caution is warranted since anti-
depressant therapy in children and adolescents is associ-
ated with increased rates of suicidal ideation [4–6].
Aripiprazole (ARP), a dopamine D2 receptor partial agon-
ist, is different from other atypical antipsychotics, which
usually have the profiles of D2 receptor antagonists.
Moreover, ARP exhibits 5-HT2a receptor antagonism and
5-HT1a receptor partial agonism [7]. We present a puber-
tal patient with TTM, which was markedly improved on* Correspondence: sasaki@faculty.chiba-u.jp
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creativecommons.org/publicdomain/zero/1.0/low-dose ARP (1.5 mg/day) after failing to respond to
fluvoxamine (50 mg/day) and comprehensive CBT.Case presentation
A 14-year-old girl, accompanied by her mother, was seen
at our hospital for treatment of trichotillomania (TTM).
She had exhibited compulsive hair pulling since the age
of 11. The condition had resulted in considerable hair
loss, which over the preceding 3 years she had attempted
to mask by wearing a wig or bandana. She had undergone
several treatments for hair pulling, including school
counseling and psychoeducation for her family. Most
recently, she had been receiving treatment with a SSRI
(fluvoxamine 50 mg/day), which was initiated at an-
other psychiatric clinic 2 years earlier. However, her
symptoms of TTM did not improve. She reported that
she continued to pull her hair out despite repeated
attempts to stop or decrease this activity, and the hair
pulling had caused clinically significant distress or im-
pairment in social areas. Her score on the Massachusetts
General Hospital Hair Pulling Scale (MGH-HPS) [8] was
23, and she was given a diagnosis of TTM according to
the DSM-5 criteria [1].
We discontinued her previous medication and started
comprehensive CBT for approximately 4 months. How-
ever, her hair-pulling symptoms did not improve, and she
did not wish to continue comprehensive CBT. Therefore,
we discontinued the comprehensive CBT and initiatedarticle distributed under the terms of the Creative Commons Attribution
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pulling symptoms were dramatically improved without
extrapyramidal symptoms like sedation, weight gain, and
nausea. Her MGH-HPS was reduced to six. No abnormal-
ities were found in her general laboratory examinations.
She has experienced no recrudescence of hair-pulling
symptoms or extrapyramidal symptoms like sedation,
weight gain, and nausea and has consistently attended
school for the past 6 months.
The present case is of a 14-year-old female with TTM
that was treated with a low dose of ARP 1.5 mg/day. To
our knowledge, this is the first published report to show
an improvement of pubertal TTM using an ultra-low
dose of ARP. In this case, a 50-mg fluvoxamine mono-
therapy for 2 years and a subsequent 4-month CBT
monotherapy did not improve her hair-pulling symp-
toms. However, the treatment with a low-dose ARP of
1.5 mg/day dramatically improved her TTM symptoms
without extrapyramidal symptoms.
Recently, ARP has been reported to improve the TTM
symptoms of adult patients [9, 10]. In addition, it has
been reported that only 1.5 to 3.0 mg/day of ARP alone
improved TTM symptoms in a 20-year-old man [11]. In
keeping with these findings, a small (n = 11) open-label
study suggested that ARP was a promising treatment for
TTM in adults [12].
The results of a previous study [13] led to the inclusion
of TTM in a new section of DSM-5, entitled Obsessive-
Compulsive and Related Disorders [1]. However, TTM is
not characterized by obsessional thoughts, and a greater
overlap may be evident with other obsessive-compulsive
spectrum disorders, such as skin picking and tic disorders
[14]. A recent study showed that ARP was effective for the
treatment of tic disorders in children and adolescents
while causing only mild adverse effects [15]. Furthermore,
Our previous report suggested that ARP might have
advantages, especially in cases of a defective general status
without extrapyramidal symptoms [16]. ARP may correct
TTM by stabilizing dopamine in the prefrontal cortex,
thereby improving motor inhibition deficits [7]. These
findings suggest that the pathology of TTM may resemble
that of tic disorders. In other words, TTM may be more
closely aligned with addictions and disorders of habit, or
tic disorders such as Tourette syndrome, than with OCD.
The main limitation of this case report was the small
sample size (n = 1). Furthermore, fluvoxamine treatment
dose of 50 mg/day might be too low for definition of
SSRI resistance. It is reported that the existing trials of
TTM have very small sample sizes, and the body of
evidence is of low quality, mostly clinical trials where a
target was more than 18 years old (only one trial in-
cluded a 16 year-old-subject) [2]. So, the appropriate
capacity of fluvoxamine, other SSRI, atypical, or typical
antipsychotics for treatment of TTM in children andadolescents is still unknown. However, low-dose ARP
treatment for TTM might be a safe alternative to antide-
pressants, which carry the risk of agitation with suicidal
ideation in adolescents. In this regard, the mechanisms
underlying the effects of low-dose ARP in the present
case remain unclear, but our results do suggest that low-
dose ARP may be advantageous, particularly in pubertal
TTM cases like the present one.
Conclusions
We reported the case of a female pubertal patient with
TTM who was treated successfully using low-dose ARP
(1.5 mg/day) monotherapy.
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